Document:

EX-10.1

Exhibit 10.1

TWENTY-NINTH AMENDMENT TO CREDIT AGREEMENT

          TWENTY-NINTH AMENDMENT, dated as of May 5, 2009 (this “Amendment”), to the Credit and
Guaranty Agreement, dated as of July 19, 2007, as amended by the First Amendment and Waiver to
Credit Agreement, dated as of November 9, 2007, the Second Amendment to Credit Agreement, dated as
of March 12, 2008, the Third Amendment to Credit Agreement, dated as of March 26, 2008, the Fourth
Amendment to Credit Agreement, dated as of July 18, 2008, the Fifth Amendment to Credit Agreement,
dated as of July 24, 2008, the Sixth Amendment to Credit Agreement, dated as of August 25, 2008,
the Seventh Amendment to Credit Agreement, dated as of September 30, 2008, the Eighth Amendment to
Credit Agreement, dated as of October 2, 2008, the Ninth Amendment to Credit Agreement, dated as of
October 29, 2008, the Tenth Amendment to Credit Agreement, dated as of November 6, 2008, the
Eleventh Amendment to Credit Agreement, dated as of November 14, 2008, the Twelfth Amendment to
Credit Agreement, dated as of November 21, 2008, the Thirteenth Amendment to Credit Agreement,
dated as of December 4, 2008, the Fourteenth Amendment to Credit Agreement, dated as of December
19, 2008, the Fifteenth Amendment to Credit Agreement, dated as of January 5, 2009, the Sixteenth
Amendment to Credit Agreement, dated as of January 16, 2009, the Seventeenth Amendment to Credit
Agreement, dated as of February 5, 2009, the Eighteenth Amendment to Credit Agreement, dated as of
February 17, 2009, the Nineteenth Amendment to Credit Agreement, dated as of February 23, 2009, the
Twentieth Amendment to Credit Agreement, dated as of March 3, 2009, the Twenty-First Amendment to
Credit Agreement, dated as of March 10, 2009, the Twenty-Second Amendment to Credit Agreement,
dated as of March 17, 2009, the Twenty-Third Amendment to Credit Agreement, dated as of March 24,
2009, the Twenty-Fourth Amendment to Credit Agreement, dated as of March 25, 2009, the Twenty-Fifth
Amendment to Credit Agreement, dated as of March 31, 2009, the Twenty-Sixth Amendment to Credit
Agreement, dated as of April 7, 2009, the Twenty-Seventh Amendment to Credit Agreement, dated as of
April 21, 2009, the Twenty-Eighth Amendment to Credit Agreement, dated as of April 28, 2009 and
that certain letter agreement dated February 26, 2008 (as further amended, restated or otherwise
modified from time to time, the “Credit Agreement”), by and among Proliance International
Inc., a Delaware corporation (“Holdings” and the “Borrower”), certain domestic
subsidiaries of the Borrower listed as a “Guarantor” on the signature pages thereto (together with
each other Person (as defined in the Credit Agreement) that guarantees all or any portion of the
Obligations (as defined in the Credit Agreement) from time to time, each a “Guarantor” and
collectively, the “Guarantors”), the lenders from time to time party thereto (each a
“Lender” and collectively, the “Lenders”), Silver Point Finance, LLC, a Delaware
limited liability company (“Silver Point”), as collateral agent for the Agents (as
hereinafter defined) and the Lenders (in such capacity, together with its successors and assigns in
such capacity, if any, the “Collateral Agent”), and as administrative agent for the Agents
and the Lenders (in such capacity, together with its successors and assigns in such capacity, if
any, the “Administrative Agent” and together with the Collateral Agent, each an
“Agent” and collectively, the “Agents”) and Silver Point as lead arranger (in such
capacity, together with its successors and assigns in such capacity, if any, the “Lead
Arranger”).

          WHEREAS, capitalized terms used in these recitals shall have the respective meanings set forth
in the Credit Agreement unless otherwise defined herein.

 

 

          WHEREAS, the Credit Parties have requested that the Agents and the Lenders amend certain
provisions of the Credit Agreement, subject to the terms and conditions set forth in this
Amendment.

          WHEREAS, the Agent and the Lenders are willing to agree to this requested Amendment, but only
upon the terms and subject to the conditions set forth herein.

          NOW, THEREFORE, in consideration of the foregoing and the mutual promises contained herein,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Credit Parties, the Agents and the Lenders hereby agree as follows:

          1. Definitions. All capitalized terms used herein and not otherwise defined herein
are used herein as defined in the Credit Agreement.

          2. Defined Terms in the Credit Agreement. Section 1.1 of the Credit Agreement is
hereby amended, as follows:

     (a) New Definitions. Section 1.1 of the Credit Agreement is hereby amended by adding
the definitions of the following terms thereto, in alphabetical order, to read in their entirety as
follows:

     “‘Twenty-Ninth Amendment’ means the Twenty-Ninth Amendment to the Credit Agreement, dated as
of May 5, 2009, by and among the Credit Parties, the Requisite Lenders and the Agents.”

     “‘Twenty-Ninth Amendment Effective Date’ has the meaning ascribed to the term “Twenty-Ninth
Amendment Effective Date” in the Twenty-Ninth Amendment.”

          3. Section 2.23 — Waiver Reserve. Section 2.23 of the Credit Agreement is hereby
amended and restated in its entirety to read as follows:

     “2.23 Waiver Reserve. The Agents, the Borrowing Base Agent, the Lenders, the Borrower and
the Guarantors hereby agree that as of the date hereof a reserve in the amount of $0 has been
established against the Borrowing Base (the “Waiver Reserve”) and such Waiver Reserve shall
be increased to $7,250,000 on the earliest of (x) the occurrence of an Event of Default, other than
any Prospective Event of Default (as defined in the Twenty-Second Amendment), and (y) May 12,
2009.”

          4. Conditions to Effectiveness. This Amendment shall become effective (the
“Twenty-Ninth Amendment Effective Date”) only upon satisfaction in full of the following
conditions precedent:

          (a) Collateral Agent shall have received counterparts of this Amendment that bear the
signatures of each Credit Party, each Agent and the Requisite Lenders.

          (b) Except as set forth in the Second Amendment, the Third Amendment, the Fourth Amendment,
the Fifth Amendment, the Sixth Amendment, the Seventh Amendment, the

-2-

 

Eighth Amendment, the Ninth Amendment, the Tenth Amendment, the Eleventh Amendment, the
Twelfth Amendment, the Thirteenth Amendment, the Fourteenth Amendment, the Fifteenth Amendment, the
Sixteenth Amendment, the Seventeenth Amendment, the Eighteenth Amendment, the Nineteenth Amendment,
the Twentieth Amendment, the Twenty-First Amendment, the Twenty-Second Amendment, the Twenty-Third
Amendment, the Twenty-Fourth Amendment, the Twenty-Fifth Amendment, the Twenty-Sixth Amendment, the
Twenty-Seventh Amendment, the Twenty-Eighth Amendment and this Amendment, the representations and
warranties contained herein, in Section IV of the Credit Agreement and in each other Credit
Document are true and correct in all material respects on and as of the Twenty-Ninth Amendment
Effective Date as though made on and as of such date, except to the extent that any such
representation or warranty expressly relates solely to an earlier date (in which case such
representation or warranty shall be true and correct in all material respects on and as of such
earlier date).

          (c) Borrower shall have paid to Administrative Agent all amounts due and owing to any Agent or
any Lender in connection with this Amendment and the Credit Documents.

          (d) Except as expressly waived herein, no Default or Event of Default shall have occurred and
be continuing on the Twenty-Ninth Amendment Effective Date or would result from this Amendment
becoming effective in accordance with its terms.

          (e) All legal matters incident to this Amendment shall be reasonably satisfactory to the
Agents and their respective counsel.

          5. Representations and Warranties. Each Credit Party represents and warrants as
follows:

          (a) Organization, Good Standing, Etc. Each Credit Party (i) is a corporation, limited
liability company or limited partnership, duly organized, validly existing and in good standing
under the laws of the state or jurisdiction of its organization, (ii) has all requisite power and
authority to execute and deliver this Amendment, consummate the transactions contemplated hereby
and perform the Credit Agreement, as amended and modified hereby and (iii) is duly qualified to do
business and is in good standing in each jurisdiction in which the character of the properties
owned or leased by it or in which the transaction of its business makes such qualification
necessary other than in such jurisdictions where the failure to be so qualified and in good
standing could not reasonably be expected to have a Material Adverse Effect.

          (b) Authorization, Etc. The execution, delivery and performance by each Credit Party
of this Amendment and the performance by each Credit Party of the Credit Agreement, as amended and
modified hereby (i) have been duly authorized by all necessary action, (ii) do not and will not
contravene its charter or by-laws, its limited liability company or operating agreement or its
certificate of partnership or partnership agreement, as applicable, or any applicable law, or any
contractual restriction binding on or otherwise affecting it or any of its properties, (iii) do not
and will not result in or require the creation of any Lien (other than pursuant to any Credit
Document) upon or with respect to any of its properties, and (iv) do not and will not result in any
default, noncompliance, suspension, revocation, impairment, forfeiture

-3-

 

or nonrenewal of any material permit, license, authorization or approval applicable to its
operations or any of its properties.

          (c) Governmental Approvals. No authorization or approval or other action by, and no
notice to or filing with, any Governmental Authority is required in connection with the due
execution, delivery and performance by any Credit Party of this Amendment or the performance by any
Credit Party of the Credit Agreement, as amended and modified hereby.

          (d) Enforceability of Credit Documents. Each of this Amendment and the Credit
Agreement, as amended and modified hereby, is a legal, valid and binding obligation of the Credit
Parties which are party hereto or thereto, enforceable against such Credit Parties in accordance
with its terms, except as enforceability may be limited by equitable principles and by applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’
rights generally.

          (e) Representations and Warranties; No Default. Except as set forth in the Second
Amendment, the Third Amendment, the Fourth Amendment, the Fifth Amendment, the Sixth Amendment, the
Seventh Amendment, the Eighth Amendment, the Ninth Amendment, the Tenth Amendment, the Eleventh
Amendment, the Twelfth Amendment, the Thirteenth Amendment, the Fourteenth Amendment, the Fifteenth
Amendment, the Sixteenth Amendment, the Seventeenth Amendment, the Eighteenth Amendment, the
Nineteenth Amendment, the Twentieth Amendment, the Twenty-First Amendment, the Twenty-Second
Amendment, the Twenty-Third Amendment, the Twenty-Fourth Amendment, the Twenty-Fifth Amendment, the
Twenty-Sixth Amendment, the Twenty-Seventh Amendment, the Twenty-Eighth Amendment and this
Amendment, the representations and warranties contained herein, in Section IV of the Credit
Agreement and in each other Credit Document are true and correct in all material respects on and as
of the Twenty-Ninth Amendment Effective Date as though made on and as of such date, except to the
extent that any such representation or warranty expressly relates solely to an earlier date (in
which case such representation or warranty shall be true and correct in all material respects on
and as of such earlier date); and, except as expressly waived herein, no Default or Event of
Default shall have occurred and be continuing on the Twenty-Ninth Amendment Effective Date or would
result from this Amendment becoming effective in accordance with its terms.

          6. Effect of Amendment; Continued Effectiveness of the Credit Agreement.

          (a) Ratifications. Except as otherwise expressly provided herein, (i) the Credit
Agreement and the other Credit Documents are, and shall continue to be, in full force and effect
and are hereby ratified and confirmed in all respects, except that on and after the Twenty-Ninth
Amendment Effective Date (A) all references in the Credit Agreement to “this Agreement”, “hereto”,
“hereof”, “hereunder” or words of like import referring to the Credit Agreement shall mean the
Credit Agreement as amended and modified by this Amendment, and (B) all references in the other
Credit Documents to the “Credit Agreement”, “thereto”, “thereof”, “thereunder” or words of like
import referring to the Credit Agreement shall mean the Credit Agreement as amended and modified by
this Amendment, (ii) to the extent that the Credit Agreement or any other Credit Document purports
to pledge to the Collateral Agent, or to grant to the Collateral Agent a security interest in or
lien on, any collateral as security for the

-4-

 

Obligations or the Guaranteed Obligations, such pledge or grant of a security interest or lien
is hereby ratified and confirmed in all respects, and (iii) the execution, delivery and
effectiveness of this Amendment shall not operate as an amendment of any right, power or remedy of
the Agents or the Lenders under the Credit Agreement or any other Credit Document, nor constitute
an amendment of any provision of the Credit Agreement or any other Credit Document. This Amendment
shall be effective only in the specific instances and for the specific purposes set forth herein
and does not allow for any other or further departure from the terms and conditions of the Credit
Agreement or any other Credit Document, which terms and conditions shall remain in full force and
effect.

          (b) No Waivers. Except as expressly set forth herein, this Amendment is not a waiver
of, or consent to, any Default or Event of Default now existing or hereafter arising under the
Credit Agreement or any other Credit Document and the Agents and the Lenders expressly reserve all
of their rights and remedies under the Credit Agreement and the other Credit Documents in respect
of all such Defaults or Events of Default not waived or consented to hereby, by the Second
Amendment, by the Third Amendment, by the Fourth Amendment, by the Fifth Amendment, by the Sixth
Amendment, the Seventh Amendment, the Eighth Amendment, the Ninth Amendment, the Tenth Amendment,
the Eleventh Amendment, the Twelfth Amendment, the Thirteenth Amendment, the Fourteenth Amendment,
the Fifteenth Amendment, the Sixteenth Amendment, Seventeenth Amendment, the Eighteenth Amendment,
the Nineteenth Amendment, the Twentieth Amendment, the Twenty-First Amendment, the Twenty-Second
Amendment, the Twenty-Third Amendment, the Twenty-Fourth Amendment, the Twenty-Fifth Amendment, the
Twenty-Sixth Amendment, the Twenty-Seventh Amendment or the Twenty-Eighth Amendment, under
applicable law or otherwise.

          (c) Amendment as Credit Document. Each Credit Party confirms and agrees that this
Amendment shall constitute a Credit Document under the Credit Agreement. Accordingly, it shall be
an Event of Default under the Credit Agreement if any representation or warranty made or deemed
made by any Credit Party under or in connection with this Amendment shall have been incorrect in
any material respect when made or deemed made or if any Credit Party fails to perform or comply
with any covenant or agreement contained herein.

          7. Release. Each Credit Party hereby acknowledges and agrees that: (a) neither it
nor any of its Affiliates has any claim or cause of action against any Agent, the Borrowing Base
Agent or any Lender (or any of their respective Affiliates, officers, directors, employees,
attorneys, consultants or agents) and (b) each Agent, the Borrowing Base Agent, and each Lender has
heretofore properly performed and satisfied in a timely manner all of its obligations to the Credit
Parties and their Affiliates under the Credit Agreement and the other Credit Documents.
Notwithstanding the foregoing, the Agents, the Borrowing Base Agent and the Lenders wish (and the
Credit Parties agree) to eliminate any possibility that any past conditions, acts, omissions,
events or circumstances would impair or otherwise adversely affect any of the Agents’, the
Borrowing Base Agent’s and the Lenders’ rights, interests, security and/or remedies under the
Credit Agreement and the other Credit Documents. Accordingly, for and in consideration of the
agreements contained in this Amendment and other good and valuable consideration, each Credit Party
(for itself and its Affiliates and the successors, assigns, heirs and representatives of each of
the foregoing) (collectively, the “Releasors”) does hereby fully, finally, unconditionally
and irrevocably release and forever discharge each Agent, the Borrowing Base

-5-

 

Agent, each Lender and each of their respective Affiliates, officers, directors, employees,
attorneys, consultants and agents (collectively, the “Released Parties”) from any and all
debts, claims, obligations, damages, costs, attorneys’ fees, suits, demands, liabilities, actions,
proceedings and causes of action, in each case, whether known or unknown, contingent or fixed,
direct or indirect, and of whatever nature or description, and whether in law or in equity, under
contract, tort, statute or otherwise (collectively, “Claims”), which any Releasor has
heretofore had or now or hereafter can, shall or may have against any Released Party by reason of
any act, omission or thing whatsoever done or omitted to be done (collectively, “Actions”)
on or prior to the Twenty-Ninth Amendment Effective Date arising out of, connected with or related
in any way to this Amendment, the Credit Agreement or any other Credit Document, or any act, event
or transaction related or attendant thereto done or omitted to be done on or prior to the
Twenty-Ninth Amendment Effective Date, or the agreements of any Agent, the Borrowing Base Agent or
any Lender contained therein, or the possession, use, operation or control of any of the assets of
any Credit Party, or the making of any Loans or other advances, or the management of such Loans or
advances or the Collateral on or prior to the Twenty-Ninth Amendment Effective Date. For the
avoidance of doubt, nothing contained in this Amendment shall be deemed to release or discharge any
Released Party from any Claims arising out of, in connection with or related in any way to Actions
occurring after the date of this Amendment.

          8. Miscellaneous.

          (a) Counterparts. This Amendment may be executed in any number of counterparts and by
different parties hereto in separate counterparts, each of which shall be deemed to be an original,
but all of which taken together shall constitute one and the same agreement. Delivery of an
executed counterpart of this Amendment by telefacsimile or electronic mail shall be equally
effective as delivery of an original executed counterpart of this Amendment.

          (b) Headings. Section and paragraph headings herein are included for convenience of
reference only and shall not constitute a part of this Amendment for any other purpose.

          (c) Governing Law. This Amendment shall be governed by, and construed in accordance
with, the laws of the State of New York.

          (d) Expenses. The Borrower will pay on demand all reasonable fees, costs and expenses
of the Agents, the Borrowing Base Agent and the Lenders in connection with the preparation,
execution and delivery of this Amendment and all documents incidental hereto, including, without
limitation, the reasonable fees, disbursements and other charges of Schulte Roth & Zabel LLP,
counsel to Administrative Agent and Collateral Agent, and of McGuireWoods LLP, counsel to Borrowing
Base Agent. In addition, the Borrower will pay all costs and expenses, including attorneys’ fees
(including allocated costs of internal counsel) and costs of settlement, incurred by any Agent,
Borrowing Base Agent and Lenders in enforcing any Obligations of or in collecting any payments due
from any Credit Party hereunder or under the other Credit Documents by reason of any Default or
Event of Default (including in connection with the sale of, collection from, or other realization
upon any of the Collateral or the enforcement of the Guaranty) or in connection with any
refinancing or restructuring of the credit

-6-

 

arrangements provided hereunder in the nature of a “work out” or pursuant to any insolvency or
bankruptcy cases or proceedings (including, without limitation, the costs and expenses of any
advisers retained by Agents, the Borrowing Base Agent and Lenders; provided, that so long
as no Event of Default has occurred and is continuing the Borrower shall not be responsible for
costs and expenses of CRS in excess of $25,000).

[Remainder of this page intentionally left blank]

-7-

 

          IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their
respective officers thereunto duly authorized, as of the date first above written.

	 	 	 	 	 
	 	BORROWER:

PROLIANCE INTERNATIONAL, INC.

 	 
	 	By:  	/s/ Arlen F. Henock
 	 
	 	 	Name:  	Arlen F. Henock 	 
	 	 	Title:  	Executive Vice President, Chief

Financial Officer 	 
	 
	 	GUARANTORS:

AFTERMARKET LLC

 	 
	 	By:  	/s/ Arlen F. Henock
 	 
	 	 	Name:  	Arlen F. Henock 	 
	 	 	Title:  	Vice President 	 
	 
	 	AFTERMARKET DELAWARE CORPORATION

 	 
	 	By:  	/s/ Arlen F. Henock
 	 
	 	 	Name:  	Arlen F. Henock 	 
	 	 	Title:  	Vice President 	 
	 
	 	PROLIANCE INTERNATIONAL HOLDING CORPORATION

 	 
	 	By:  	/s/ Arlen F. Henock
 	 
	 	 	Name:  	Arlen F. Henock 	 
	 	 	Title:  	President 	 

 

 

	 	 	 	 	 
	 	AGENTS AND LEAD ARRANGER:

SILVER POINT FINANCE, LLC, as 
Administrative
Agent, Lead Arranger and 
Collateral Agent
 	 
	 
	 	By:  	/s/ Zachary M. Zeitlin
 	 
	 	 	Name:  	Zachary M. Zeitlin 	 
	 	 	Title:  	Authorized Signatory 	 
	 
	 	LENDERS:

SPF CDO I, LTD., as a Lender

 	 
	 	By:  	/s/ Zachary M. Zeitlin
 	 
	 	 	Name:  	Zachary M. Zeitlin 	 
	 	 	Title:  	Authorized Signatory 	 
	 
	 	FIELD POINT I, LTD. as a Lender

 	 
	 	By:  	/s/ Zachary M. Zeitlin
 	 
	 	 	Name:  	Zachary M. Zeitlin 	 
	 	 	Title:  	Authorized Signatory 	 
	 
	 	FIELD POINT II, LTD. as a Lender

 	 
	 	By:  	
/s/ Zachary M. Zeitlin
 	 
	 	 	Name:  	Zachary M. Zeitlin 	 
	 	 	Title:  	Authorized Signatory 	 
	 
	 	FIELD POINT III, LTD. as a Lender

 	 
	 	By:  	/s/ Zachary M. Zeitlin
 	 
	 	 	Name:  	Zachary M. Zeitlin 	 
	 	 	Title:  	Authorized Signatory 	 

 

 

	 	 	 	 	 
	 	FIELD POINT IV, LTD. as a Lender

 	 
	 	By:  	/s/ Zachary M. Zeitlin
 	 
	 	 	Name:  	Zachary M. Zeitlin 	 
	 	 	Title:  	Authorized Signatory 	 

 

 

	 	 	 	 	 
	 	BORROWING BASE AGENT AND LENDER:

WELLS FARGO FOOTHILL, LLC, as 
Borrowing Base
Agent and a Lender

 	 
	 	By:  	/s/ Jonathan Boynton
 	 
	 	 	Name:  	Jonathan Boynton 	 
	 	 	Title:  	VPEX-4.11

Exhibit 4.11

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN

THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN

OMITTED AND FILED SEPARATELY WITH THE

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO

RULE 24B-2 OF THE SECURITIES EXCHANGE

ACT OF 1934, AS AMENDED

AMENDMENT TO PATENT LICENSE AGREEMENT

This Agreement is made by and between:

NOVOGEN LIMITED ACN 063 259 754 and NOVOGEN RESEARCH PTY LIMITED ACN 060 202 931 each with its
principal place of business at 140 Wicks Road, North Ryde, NSW 2113, Australia and NOVOGEN INC. of
1013 Centre Road, Wilmington, Delaware, United States of America (hereinafter together referred to
as “Novogen”)

AND

SOLAE, LLC (formerly Protein Technologies International, Inc.) which is a corporation of the state
of Delaware, having its principal place of business at 1034 Danforth Dr., St. Louis, Missouri
63102, United States of America (hereinafter “Solae”)

BACKGROUND:

	A.	 	Novogen and Solae desire to amend the Patent License Agreement to change the schedule of
annual minimum payments.
	 
	B.	 	Novogen and Solae desire to amend the Patent License Agreement to allocate to Novogen an
interest in any potential sale of Solae’s isoflavone drug program.
	 
	C.	 	Novogen and Solae desire to amend the Patent License Agreement to provide a mechanism for
enjoining infringement of products containing isoflavones derived from kudzu that fall within
the Patent Rights.

THE PARTIES AGREE AS FOLLOWS:

	1.	 	This Agreement amends the Patent License Agreement of November 13, 1997 between Novogen and
Protein Technologies International, Inc. (the “Patent License Agreement”) with effect on and
from 24 December 2002. Unless this Agreement expressly states otherwise, the provisions of
this Agreement are in addition to, and not in substitution or replacement of, any of the
provisions of the Patent Licence Agreement.
	 
	2.	 	Capitalised expressions in this Agreement which are not defined in this Agreement have the
same meaning as those expressions have in the Patent License Agreement.
	 
	3.	 	The annual minimum payment schedule set forth in article 3.01(b)(i-iii) if the Patent License
Agreement is deleted and is replaced with the following annual minimum payment schedule:

     3.01(b)

 

 

	 	(i)	 	[***]1 dollars (U.S. $[***]) due by December 31,
2001;
	 
	 	(ii)	 	[***] dollars (U.S. $[***) due by December 31, 2002;
	 
	 	(iii)	 	[***] dollars (U.S. $[***]) due by December 31, 2003;
	 
	 	(iv)	 	[***] dollars (U.S. $[***]) due by December 31, 2004;
	 
	 	(v)	 	[***] dollars (U.S. $[***]) due by December 31, 2005;
	 
	 	(vi)	 	[***] dollars (U.S. $[***]) due by December 31, 2006;
	 
	 	(vii)	 	One and a quarter million dollars (U.S. $1,250,000) due by December 31, 2007;
	 
	 	(viii)	 	One million, three hundred and twenty thousand dollars (U.S. $1,320,000) due by December 31, 2008;
	 
	 	(ix)	 	One million, four hundred and thirty thousand dollars (U.S. $1,430,000) due by December 31, 2009;
	 
	 	(x)	 	One million, five hundred and forty thousand dollars (U.S. $1,540,000) due by December 31, 2010;
	 
	 	(xi)	 	One million, six hundred and seventy thousand dollars (U.S. $1,670,000) due by December 31, 2011;
	 
	 	(xii)	 	Two million dollars (U.S. $2,000,000) by December 31, 2012 and annually thereafter for so long as this Agreement is in effect;
	 
	 	(xiii)	 	An additional five hundred thousand dollars (U.S. $500,000) due on the issue of a U.S. patent having claims to a health supplement comprising any two or more naturally occurring phytoestrogens selected from genistein, daidzein, and/or their glycosides.

	4.	 	If Solae sells, transfers of otherwise disposes of (“Sells”) the whole or a substantial part
of its assets forming part of its genistein/prostate drug program (the Joint Development
Program between the US National Cancer Institute and Solae) (the “Drug Program”) to any third
party, then Solae shall pay to Novogen the first [***] dollars (U.S. $[***]) of revenue
derived from or in connection with that Sale, payable in accordance with the following payment
schedule:

	 	(a)	 	If Solae Sells the Drug Program in the 2003 Calendar Year, three payments as
follows:

	 	(i)	 	[***] dollars (U.S. $[***]) payable immediately upon the
initial receipt of the revenue by Solae or its Affiliate;
	 
	 	(ii)	 	an additional payment of [***] dollars (U.S. $[***]) on the
first anniversary in 2004 of the initial receipt of the revenue by Solae or its
Affiliate; and
	 
	 	(iii)	 	an additional payment of [***] dollars (U.S. $[***]) on the
second anniversary in 2005 of the initial receipt of the revenue by Solae or
its Affiliate.

	 	(b)	 	If Solae Sells the Drug Program in the 2004 Calendar Year, two payments as
follows:

	 	(i)	 	[***] dollars (U.S. $[***]) payable immediately upon the
initial receipt of the revenue by Solae or its Affiliate; and
	 
	 	(ii)	 	an additional payment of [***] dollars (U.S. $[***]) on the
first anniversary in 2005 of the initial receipt of the revenue by Solae or its
Affiliate.

 

			
	1	 	[***] Confidential treatment requested.

-2-

 

	 	(c)	 	If Solae Sells the Drug Program after 31 December 2004, a payment of [***]
dollars (U.S. $[***]) payable immediately upon the initial receipt of the revenue by
Solae or its Affiliate.

If Solae enters into any transaction to Sell the whole or a substantial part of its assets
forming part of the Drug Program under which Solae or any Affiliate receives or will receive
revenue of less than U.S. $[***] but receives or will receive additional consideration other
than money (“Other Consideration”), then Solae shall transfer or assign to Novogen (or
otherwise ensure that Novogen receives) on or before the date on which Solae or any
Affiliate receives the Other Consideration, a portion of the Other Consideration which
ensures that the total consideration received by Novogen in relation to the Sale in money or
money’s worth is not less than the amounts set out in paragraphs (a), (b) or (c) above.
Solae shall at all times observe fiduciary duties to and act in good faith toward Novogen in
relation to any transaction to Sell the whole or a substantial part of Solae’s assets
forming part of the Drug Program.

	5.	 	In order to abate infringement of the Patent Rights in so far as they pertain to isoflavone
materials which are derived from kudzu, the parties agree that if it reasonably appears to
Novogen:

	 	(a)	 	that a Third Party is, without the license of Novogen, making, using, selling,
offering for sale, or importing any product in the Territory which contains isoflavone
materials which are derived from kudzu;
	 
	 	(b)	 	that the product infringes the Patent Rights; and
	 
	 	(c)	 	that retail sales of the product are greater than four million dollars (U.S.
$4,000,000) per annum in the Territory,

	 	 	then Novogen shall, within a reasonable time after receiving Solae’s request in writing,
initiate an action at law or in equity against the Third Party for infringement of the
Patent Rights.
	 
	6.	 	If Novogen initiates an action at Solae’s request under clause 5, then:

	 	(a)	 	Solae shall be entitled to join such action as a party to the suit (insofar as
permitted by law);
	 
	 	(b)	 	if Solae is joined as a party to the suit, Solae shall be entitled to have the
conduct and control of and prosecute the suit, any counterclaim filed in the suit and
any appeal therefrom (the “Litigation”), but Solae shall observe any direction which
Novogen gives in relation to any issue in the Litigation relating to the validity of
any Patent Rights;
	 
	 	(c)	 	if Solae is not joined as a party to the suit, Solae shall be entitled to have
the conduct and control of and prosecute the Litigation in Novogen’s name, but Solae
shall observe any direction which Novogen gives in relation to any issue in the
Litigation relating to the validity of any Patent Rights;
	 
	 	(d)	 	Solae shall be responsible for all legal and other costs incurred by the
parties in initiation, prosecution and conduct of the Litigation; and
	 
	 	(e)	 	Solae shall indemnify Novogen against, and pay to Novogen on demand the amount
of, all losses, damages, costs and expenses suffered or incurred by or on behalf of
Novogen in or in relation to the initiation, prosecution and conduct of the Litigation,
including legal and patent attorney expenses on an indemnity basis, the time of
Novogen’s management, scientific and technical personnel (calculated hourly on a full
time equivalent basis), and any loss or damage as a result of any orders made in the
Litigation, except that Solae shall not be responsible for indemnifying Novogen for any
expenses or costs incurred by Novogen that result from Novogen’s independent

-3-

 

	 	 	 	prosecution and conduct of the Litigation and that do not result from Solae’s
prosecution and conduct of the Litigation or from Solae’s specific requests for
Novogen’s assistance regarding the Litigation, and Solae shall not be responsible
for any loss or damage incurred by Novogen as a result of any court findings or
order in the Litigation resulting in the invalidation of any patent within the
Patent Rights.

-4-

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives effective as of the date of the last signature below.

	 	 	 	 	 	 	 
	Novogen Limited	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 	 	Date:
	 	 

	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Novogen Research Pty Limited	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 	 	Date:
	 	 

	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Novogen Inc.	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 	 	Date:
	 	 

	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Solae, LLC	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 	 	Date:
	 	 

	 	 
	 	 	 	 	 	 	 

-5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]